Achieving launch excellence in orphan medicinesNew rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking Share XAchieving launch excellence in orphan medicineshttps://pharmaphorum.com/market-access-2/achieving-launch-excellence-in-orphan-medicines/
Launch excellence in a disrupted world – challenges & opportunitiesOverview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care Share XLaunch excellence in a disrupted world – challenges & opportunitieshttps://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/
Orphan medicines launch excellence: sustaining launch successOverview Launching orphan medicines excellently will become even more important over the next five years as more patients Share XOrphan medicines launch excellence: sustaining launch successhttps://pharmaphorum.com/market-access-2/orphan-medicines-launch-excellence-sustaining-launch-success/
Simulated data, real-world patient insightsThe UK has some of the best patient data available anywhere in the world, and a preeminent position in Share XSimulated data, real-world patient insightshttps://pharmaphorum.com/views-and-analysis/simulated-data-real-world-patient-insights/
Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?Drug development can be quite a risky business at the best of times, but particularly in the biotech Share XBiotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?https://pharmaphorum.com/views-and-analysis/biotech-in-post-brexit-britain-the-future-for-the-uks-pharma-innovation-engine/
The 2nd Life Sciences Sector Deal and the NHS 10 Year PlanOverview Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK Share XThe 2nd Life Sciences Sector Deal and the NHS 10 Year Planhttps://pharmaphorum.com/market-access-2/the-2nd-life-sciences-sector-deal-and-the-nhs-10-year-plan/
UCB, Roche, and IQVIA take lead in UK life sciences investmentPharma giant UCB is to invest around £1 billion in the UK as part of a second life Share XUCB, Roche, and IQVIA take lead in UK life sciences investmenthttps://pharmaphorum.com/news/ucb-roche-and-iqvia-take-lead-in-uk-life-sciences-investment/
Can simulated datasets unlock the potential of patient data?Overview Patient level data offers the promise of insights which can craft new and better pathways, enable development Share XCan simulated datasets unlock the potential of patient data?https://pharmaphorum.com/debates-insight-patients/can-simulated-datasets-unlock-the-potential-of-patient-data/
Realising the biotech promise: addressing the path to marketOverview Now more than ever before, biotech is the engine for innovation in medicine, finding, creating and delivering Share XRealising the biotech promise: addressing the path to markethttps://pharmaphorum.com/market-access-2/addressing-the-path-to-market/
